Vascepa (icosapent ethyl) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:				
Instructions: Please fill out all important for the review (e.g., this form is Protected Health I	chart notes or lab data, to su		•	t). Information contained in		
				URGENT		
MEMBER INFORMATION						
LAST NAME:		FIRST NAME:				
PHONE NUMBER:	E NUMBER:			DATE OF BIRTH:		
STREET ADDRESS:						
CITY:	CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUM	MBER:					
MALE FEMALE HEIGHT OF THE PRESCRIF FOLLOWING LINK: PRIMETHERAPEUTICS.COM, PATIENT'S AUTHORIZED REPRESENTATIVE.	IBER, YOU WILL NEED TO SUBMIT A PHI DISCLO	OSURE AUTHORIZATION FORM	WITH THIS REQU	UEST WHICH CAN BE FOUND AT THE		
PRESCRIBER INFORMATION						
LAST NAME:		FIRST NAME:				
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:				
NPI NUMBER:		DEA NUMBER:				
PHONE NUMBER:		FAX NUMBER:				
STREET ADDRESS:						
CITY:		STATE: ZIP CODE:				
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:				
MEDICATION OR MEDICAL I	DISPENSING INFORMATION					
MEDICATION OR MEDICAL I	DISPENSING INFORMATION					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS	:	QUANTITY:		
NEW THERAPY RENEWAL IF RENEWAL: DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			INITIATED:			

Continued on next page.



Vascepa (icosapent ethyl) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
 ☐ Hypertriglyceridemia ☐ Severe hypertriglyceridemia ☐ Other diagnosis: 3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION. 	ICD-10 : PLEASE PROVIDE ALL RELEVANT CLINIC.	AL INFORMATION TO SUPPORT A	
Clinical Information:			
Initial Request: Is the prescriber a cardiologist or lipid	specialist? □ Yes □ No		
Does the patient have a recent Triglyc documentation	eride level \geq 150mg/dL and <500mg/dL	? □ Yes □ No Please submit	
Does the patient have established care	diovascular disease? 🗆 Yes 🗆 No		
Does the patient have diabetes with a □ age ≥ 65 years □ history of MI □ stroke □ peripheral artery disease (PAD) □ stent placement □ CHF □ BMI >? □ smoker □ high LDL-C ≥ 100 mg/dL when not o □ hypertension	t least 2 cardiovascular risks?	No Please submit documentation	
Does the patient have a recent LDL level Please submit documentation.	vel between 41 mg/dL and 100 mg/dL?	□ Yes □ No	
Has the patient been on statin therapy	y for at least the previous 4 weeks? \Box \	∕es □ No	
Will the patient remain on statin thera	apy while on Vascepa? 🗆 Yes 🗆 No		
For patients who have diabetes: Does by a submitted lab report dated within	the patient have a hemoglobin A1C levent the past six months? — Yes — No	el greater than 10.0%, as documented	



Vascepa (icosapent ethyl) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
Renewal Request:				
Is patient continuing to take a statin? ☐ Yes ☐ No				
For patient with severe hypertriglyceridemia, please answ	ver the following:			
Is patient's triglyceride level ≥ 500 mg/dL AND ≤ 2000 mg/dL? □ Yes □ No Please submit documentation.				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
*Please note: Not all drugs/diagnoses are covered on all p information is received.	lans. This request may be denied unless all required			
ATTESTATION: I attest the information provided is true ar the Health Plan, insurer, Medical Group or its designees m information necessary to verify the accuracy of the inform				
Prescriber Signature or Electronic I.D. Verification:	Date:			
	ssion contain confidential health information that is legally privileged. If closure, copying, distribution, or action taken in reliance on the contents mation in error, please notify the sender immediately (via return FAX)			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP – 4201

P.O. Box 64811 St. Paul, MN 55164-0811

